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ABSTRACT 
 
After identification and validation of targets in a drug development process, some 
independent lead compounds should be selected and optimized for their activities. 
Then, safety assessments and clinical trials decide whether the drug is proper to enter 
the market. Different stages of this process (and especially the identification of lead 
compounds) are extremely expensive and time-consuming. Rational drug 
development methods try to reduce the costs by optimizing the pace of drug discovery 
and reducing the number of products abandoned during development. For decades, 
many investigators have studied the ligand-protein interactions, but very few 
structured databases are devoted to such information. Herein, development of such 
databases is proposed, since it is obvious that our prior knowledge about the chemico-
biological interactions can help us choosing appropriate lead compounds without 
further experimental and computational investigations, which are usually based on 
searching in gigantic combinatorial databases of chemical compounds. 
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Biological activities are almost always 
associated with the interaction of two or 
more biomolecules: ligands bind to 
carrier proteins in blood circulation; 
substrates bind to enzymes before the 
reaction takes place; bindings of 
hormones to receptors trigger signals 
inside cells. Because of the importance of 
the subject, binding of ligands to proteins 
and other biomolecules (like DNA) has 
been studied extensively for decades.  
 
Many drugs perform their activity via 
interference with the normal action of 
certain compounds, typically with an 
inhibitory mechanism. Therefore, study 
of the biochemical properties of ligand-
protein (or in some cases, ligand-DNA) 
interaction has a central role in the 
discovery of new drugs, and is of 
commercial importance. 
 
Drug discovery entered a new era when 
results of the Human Genome Project 
were released (Lander et al., 2001). It is 
now possible to search proteins of 
differential expression patterns in the 
transcriptome and/or proteome of a 
diseased tissue. This target identification 
and validation is normally the first step in 
the drug development process (Figure 1). 
In the next step, proper inhibitors (or 
activators) for the related activity should 
be found (Nuttall, 2001), and their 
activity should be optimized by adding, 
removing and changing the compound 
substituents. Safety and toxicology 
assessments and clinical trials are the last 
steps before a drug can go to the market. 
It is obvious that our prior information 
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about the nature of these inhibitions (or 
activations) is particularly important, and 
speeds up the drug discovery process, 
and effectively reduces the development 
costs.  
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Figure 1: Drug development process. 
 
Although SAR and QSAR surveys are 
traditionally used in rational drug 
discovery, existing in silico drug design 
techniques also robustly rely on the study 
of three-dimensional structure of proteins 
associated with other molecules (Joseph-
McCarthy, 1999). Different modes of 
ligand-protein  interactions  have been 
studied in details using such data. At 
present, many researchers try to perform 
the task of “docking” novel ligands on 
the surface of a receptor or an enzyme of 
known structure, in order to find possible 
binding sites. This method seems 
promising, but accurate high-throughput 
screening for a ligand with desired 
properties can be extremely time-
consuming, since the bigger the 
combinatorial databases of chemical 
compounds, the higher the probability of 
finding a better potential drug. One 
possible modification of this approach is 
to restrict our search dataset to analogs of 
ligands of known binding affinity 
towards the target, as the probability of 
finding a ligand with desired properties 
in a dataset of analogs (structurally 
related molecules) is greater than such 
probability in a huge dataset of (random) 
molecules. It is obvious that our prior 
knowledge of ligands with known 
properties again helps in solving our 
problem. Moreover, the need for 
knowing the three-dimensional structure 
of target protein is eliminated in this 
approach. In fact, design of lead 
compounds on the basis of known 
ligands of a target protein is a major 
strategy in the development of new drugs 
(Twyman, 2004).   
 
As a result of large amounts of published 
information on molecular binding 
properties, it seems reasonable to register 
these data in specific databases. Today, 
one can find a wide variety of databases 
with different scopes, such as genomic 
information, protein structures, and 
cellular expression levels of 
biomolecules. Surprisingly, there are 
only a limited number of databases with 
the subject of ligand binding. Most of 
these databases collect information about 
ligand binding properties of complexes 
 88
with known three-dimensional structures 
(for example see Chen et al.,2002a; 
Wang et al., 2004; Golovin et al., 2005). 
BindingDB (see Chen et al., 2002b; 
2002c; Available from: 
http://www.bindingdb.org ) is the only 
database completely devoted to the 
experimental results of the interaction of 
different compounds, typically with low 
molecular weights, with biological 
macromolecules like proteins. At the 
moment, this database contains only 
experimental data obtained from 
isothermal titration calorimetry (ITC) 
and enzyme inhibition assays. At the 
moment, the database contains only a 
few thousand ITC and enzyme inhibition 
entries. Clearly this is only the tip of the 
iceberg: a massive amount of information 
on ligand binding (obtained from 
experiments that take advantage of a 
variety of techniques) has been 
accumulated in literature for years, and it 
is still growing in size.  
 
Mining data from literature is not an easy 
mission. It is practically impossible to 
study manually all the previous 
publications (or even their indexed 
abstracts) in the fields of biochemistry, 
biophysics, molecular biology, 
pharmacology and biomedical sciences; 
for example, there are at least twelve 
million abstracts indexed in Medline 
(http://www.ncbi.nlm.nih.gov/PubMed/). 
Simple searches in literature databases 
using definite keywords (as well as 
making use of MeSH vocabulary) will 
not work as well, because of the large 
number of false positive and/or false 
negative hits. As a result, it seems that 
the most reasonable method must be 
automatic capture of information using 
special computer algorithms. At present, 
no special algorithm is used in 
BindingDB to extract data from literature 
(Y. Lin, personal communication). 
 
Automatic literature searching for mining 
data has been reported previously to 
extract important biochemical and 
biomedical information (Shatkay and 
Feldman, 2003; Cohen and Hersh, 2005; 
Krallinger et al., 2005). Such 
methodologies can be applied to the 
subject of ligand-protein interactions, in 
order to highlight suspected papers; there 
will be a need to browse the related 
articles by hand in the next step, to make 
sure about the content and then to extract 
the data lied within the body of the texts 
and tables. Without such automatic 
approaches, construction of an 
integrating ligand binding database 
seems to be extremely intricate. At 
present, in our group we deal with such a 
problem, and we hope to develop a 
simple and effective algorithm to mine 
such data from literature. 
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